预约演示
更新于：2026-02-27
Terazosin Hydrochloride
盐酸特拉唑嗪
更新于：2026-02-27
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H30ClN5O6 |
InChIKeyNZMOFYDMGFQZLS-UHFFFAOYSA-N |
CAS号70024-40-7 |
关联
63
项与 盐酸特拉唑嗪 相关的临床试验NCT04760860
a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies
NCT07288450
Terazosin And Metabolic Engagement in Parkinson's Disease
NCT07224269
A Pilot Study of the Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis
100 项与 盐酸特拉唑嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸特拉唑嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸特拉唑嗪 相关的专利（医药）
登录后查看更多信息
1,165
项与 盐酸特拉唑嗪 相关的文献（医药）2026-01-02Arab Journal of Urology
Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025
Review
作者: Almurshed, Oroub Abdulaziz ; Alshammari, Adel H. ; Alsulami, Yazeed Dakhel ; Alkharboosh, Abdullah Sulaiman ; Alruhaili, Wijdan Ateeq Allah ; Alotaibi, Eman Abdullah ; Alomari, Renad Wesam ; Alotaibi, Mohammed Saad ; Almaghthawi, Mohammed Marzouq ; Alahamdi, Manar Ali ; Aljaddua, Salem Ibrahim S ; Hijazi, Eyad Mohammed
Introduction:
Alpha-blockers are widely used in medical expulsive therapy (MET) for ureteral stones; however, the current evidence regarding their comparative effectiveness remains inconsistent. We aimed to evaluate the efficacy and safety of different alpha-blockers in facilitating ureteral stone passage and identify factors influencing treatment outcomes.
Methods:
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) published between 2010 and 2025. We searched multiple databases for studies comparing alpha-blockers with control interventions or other alpha-blockers for ureteral stones ≤10 mm. Primary outcome was stone expulsion rate; secondary outcomes included time to expulsion, pain episodes, analgesic use, and adverse events. We performed subgroup analyses by alpha-blocker type, stone size, location, and treatment duration. Network meta-analysis assessed comparative effectiveness between agents.
Results:
Twenty-nine RCTs with a total of 4,256 patients were included. Alpha-blockers significantly increased stone expulsion rates compared to controls (70.9% vs. 56.5%; RR 1.25, 95% CI 1.20-1.32; Number Needed to Treat (NNT) = 7) and reduced expulsion time by approximately three-days. Efficacy was greatest for distal ureteral stones (RR 1.52; Number Needed to Treat (NNT) = 4) and stones 5-10 mm (RR 1.35; NNT = 6). Network meta-analysis revealed efficacy ranking favoring at first terazosin, followed by doxazosin then, silodosin then, tamsulosin then, alfuzosin and last the least effective was naftopidil. Alpha-blockers significantly reduced pain episodes and analgesic requirements. Adverse events were infrequent (Number Needed to Harm (NNH) = 38), with retrograde ejaculation being most common with silodosin.
Conclusion:
Alpha-blockers significantly improve the stone expulsion rates and reduce expulsion time, especially for distal ureteral stones 5-10 mm in size. While tamsulosin remains the most studied agent, our network meta-analysis suggests terazosin and doxazosin may offer superior efficacy. The favorable risk-benefit profile supports routine use of alpha-blockers for appropriately selected patients with ureteral stones.
2026-01-01NEUROBIOLOGY OF DISEASE
APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice
Article
作者: Amundsen, Nicolette M ; Yang, Kang Yi ; Lee, Yongjae ; Baker, Annie J ; Chung, Hee Jung ; Kong, Hyunjoon ; Selvin, Paul R ; Lee, Sarah S ; Lim, Ki H ; Singh, Tanveer ; Kang, Sehong ; Bridgeman, Emma ; Noblet, Hayden A
Alzheimer's disease (AD) is the leading cause of dementia, characterized by the deposition of amyloid-β plaques and neurofibrillary tangles composed of hyperphosphorylated tau. Seizures have also emerged as a prevalent clinical feature of AD and are associated with APOE4, the major genetic risk factor of AD. However, the mechanism by which APOE4 induces seizures and neuronal hyperexcitability is incompletely understood. We discovered that human APOE4 targeted replacement mice showed increased seizure severity and seizure-induced death at 5.5-7 but not 2-3 months of age compared to APOE3 mice using the kainic acid model of status epilepticus which preferentially arises from the hippocampus. While Tau burden alone did not alter seizure susceptibility in mice, APOE4 together with Tau burden enhanced seizure severity in female mice. Notably, APOE4 was associated with decreased hippocampal levels of sodium/potassium-ATPase, ATP-generating glycolytic enzymes, including phosphoglycerate kinase 1 (PGK1) and pyruvate kinase M, and ATP. While inhibition of Na+/K+- ATPase increased hippocampal neuronal activity, pharmacologically stimulating PGK1 with terazosin increased hippocampal ATP levels and decreased seizure severity in APOE4 but not APOE3 mice. Lastly, co-application of lactate dehydrogenase inhibitor sodium oxamate to prevent the conversion of pyruvate to lactate further enhanced hippocampal ATP levels and suppressed seizure severity in APOE4 mice. Together, these findings suggest that reductions in hippocampal expression of sodium/potassium-ATPase and glycolytic enzymes may underlie APOE4-associated hippocampal hyperexcitability, revealing a novel mechanistic insight. Our results also demonstrate potent anti-seizure effects of terazosin, supporting the possibility of repurposing this anti-hypertension drug to mitigate seizure comorbidity in AD.
2025-12-31International Neurourology Journal
Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis
Article
作者: Nathania, Nathania ; Lionardi, Stevan Kristian ; Wilyono, Agoes ; Supinto, Pedro Arruda ; Rinaldi, Fransiskus Xaverius ; Silalahi, Parningotan Yosi ; Niaga, Karmenia Jessica Kurnia ; Yo, Rivan
Purpose: Alpha-blockers and 5-alpha reductase inhibitors (5ARIs) are well-established treatments for symptoms of benign prostatic hyperplasia (BPH). Despite their therapeutic benefits, concerns have been raised regarding a potential association between these medications and an increased risk of dementia. However, current evidence remains inconsistent, highlighting the need for further evaluation. This study aims to assess the potential dementia risk among patients receiving alpha-blockers and 5ARIs.Methods: Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines (PROSPERO CRD42025643431), 7 databases were systematically searched through December 2024 for studies examining the association between alpha-blockers or 5ARIs and dementia risk in patients with BPH. Risk of bias was assessed using the ROBINS-I (Risk of Bias in Non-randomized Studies of Interventions) tool. A Bayesian network meta-analysis was performed to estimate risk ratios with 95% credible intervals and to generate surface under the cumulative ranking curve (SUCRA) values.Results: Five multicenter studies involving 3,650,434 patients (mean age, 71.1 years) and demonstrating an overall low risk of bias were included. The network analysis indicated that neither alpha-blockers nor 5ARIs were significantly associated with an increased risk of dementia compared with no treatment. However, SUCRA values suggested a relatively higher probability of dementia risk for 5ARIs (finasteride and dutasteride), followed by tamsulosin, doxazosin, terazosin, and alfuzosin.Conclusions: This study found no significant association between the use of alpha-blockers or 5ARIs and increased dementia risk. These findings may assist clinicians in making more informed prescribing decisions, particularly for older male patients with BPH. Further large-scale research with extended follow-up periods is needed to strengthen the evidence across all BPH medications.
100 项与 盐酸特拉唑嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 日本 | 1989-03-31 | |
| 肾性高血压 | 日本 | 1989-03-31 | |
| 高血压 | 美国 | 1987-08-07 | |
| 前列腺增生症 | 美国 | 1987-08-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
FDA_CDER 人工标引  | N/A | - | Placebo (Study 1) | 繭範觸膚鹽鑰積夢艱鑰(網獵蓋廠齋膚製築醖繭) = 遞糧壓觸範蓋構構夢範 網網壓獵顧蓋繭窪選襯 (醖淵醖鹹鑰顧鑰襯簾製 ) 更多 | 积极 | 2024-07-29 | |
(Study 1) | 繭範觸膚鹽鑰積夢艱鑰(網獵蓋廠齋膚製築醖繭) = 鑰獵構襯選選鹹壓積餘 網網壓獵顧蓋繭窪選襯 (醖淵醖鹹鑰顧鑰襯簾製 ) 更多 | ||||||
FDA_CDER 人工标引 | N/A | - | 製壓襯築廠廠積鑰餘構(襯鹽鹽顧衊淵糧蓋衊廠) = 築醖艱憲繭鑰鹽艱齋艱 壓繭獵餘鏇積憲簾窪積 (積鏇顧艱鹹壓醖繭壓夢 ) 更多 | 积极 | 2024-07-29 | ||
Placebo | 製壓襯築廠廠積鑰餘構(襯鹽鹽顧衊淵糧蓋衊廠) = 簾夢廠襯艱鏇夢廠積鏇 壓繭獵餘鏇積憲簾窪積 (積鏇顧艱鹹壓醖繭壓夢 ) 更多 | ||||||
临床1/2期 | 13 | (Active) | 襯淵積選製顧窪範鹹糧 = 齋遞艱製鏇蓋齋遞齋壓 壓願襯鬱淵遞網淵鏇齋 (醖窪窪齋壓憲淵顧窪簾, 夢鹽糧鑰鏇選顧範淵廠 ~ 壓鏇顧願齋衊鹹築築襯) 更多 | - | 2021-08-02 | ||
Placebo oral capsule (Placebo) | 襯淵積選製顧窪範鹹糧 = 齋壓網壓鬱觸築選選顧 壓願襯鬱淵遞網淵鏇齋 (醖窪窪齋壓憲淵顧窪簾, 餘憲遞壓鬱選鑰鏇構窪 ~ 糧鏇膚獵廠廠構繭築壓) 更多 | ||||||
临床2/3期 | 104 | Placebo (Placebo) | 製糧選遞製遞簾遞構積(艱選醖簾廠淵窪夢觸艱) = 糧衊蓋齋簾窪鏇繭壓願 鏇窪鹽膚窪齋獵選蓋襯 (繭簾壓艱遞糧獵積構蓋, 7.84) 更多 | - | 2015-03-02 | ||
(Terazosin) | 製糧選遞製遞簾遞構積(艱選醖簾廠淵窪夢觸艱) = 鹽鑰壓糧鹹構醖窪壓鹽 鏇窪鹽膚窪齋獵選蓋襯 (繭簾壓艱遞糧獵積構蓋, 6.03) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用